News
ALNY
147.68
-1.15%
-1.72
Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
Benzinga · 3h ago
Alnylam Pharma To Receive $25 Mln Payment From Regeneron On FDA Approval Of Livsayis
NASDAQ · 4h ago
Alnylam announces FDA approved Livsayis for treatment of gMG
TipRanks · 4h ago
Regeneron, Alnylam win FDA nod for myasthenia gravis therapy
Seeking Alpha · 4h ago
Pfizer: The Patent Cliff Fears Are Overblown
Seeking Alpha · 1d ago
Alnylam price target lowered to $254 from $369 at JPMorgan
TipRanks · 1d ago
Alnylam price target lowered to $205 from $290 at Cantor Fitzgerald
TipRanks · 2d ago
Alnylam Pharmaceuticals Price Target Cut to $250.00/Share From $455.00 by HC Wainwright & Co.
Dow Jones · 2d ago
Alnylam Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $250
Benzinga · 2d ago
Alnylam Pharmaceuticals Is Maintained at Neutral by Cantor Fitzgerald
Dow Jones · 2d ago
Alnylam Pharmaceuticals Price Target Cut to $205.00/Share From $290.00 by Cantor Fitzgerald
Dow Jones · 2d ago
Cantor Fitzgerald Maintains Neutral on Alnylam Pharmaceuticals, Lowers Price Target to $205
Benzinga · 2d ago
Alnylam tops healthcare earnings surprise list, ahead of Regeneron and Eli Lilly
Seeking Alpha · 2d ago
Alnylam price target lowered to $250 from $455 at H.C. Wainwright
TipRanks · 2d ago
Did Alnylam Pharmaceuticals' 64% Drop Catch You Out? What Bears Saw
Simply Wall St · 2d ago
Weekly Report: what happened at ALNY last week (1109-1113)?
Weekly Report · 3d ago
Is Alnylam Pharmaceuticals (ALNY) Undervalued On Strong New AMVUTTRA Data?
Simply Wall St · 4d ago
Noteworthy Friday Option Activity: ALNY, SMCI, BURL
NASDAQ · 5d ago
Arrowhead FY2026 Earnings Analysis: Pricey R&D Must Deliver As Market Turns On RNAi
Seeking Alpha · 6d ago
More
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.